JP2017535258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535258A5 JP2017535258A5 JP2017519646A JP2017519646A JP2017535258A5 JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5 JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5
- Authority
- JP
- Japan
- Prior art keywords
- site
- exogenous
- goi
- nucleic acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 230000006798 recombination Effects 0.000 claims description 26
- 238000005215 recombination Methods 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 102000018120 Recombinases Human genes 0.000 claims description 16
- 108010091086 Recombinases Proteins 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 12
- 101710163270 Nuclease Proteins 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 238000010459 TALEN Methods 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 4
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 102100034343 Integrase Human genes 0.000 claims description 3
- 108010061833 Integrases Proteins 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 102000008579 Transposases Human genes 0.000 claims description 3
- 108010020764 Transposases Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067774P | 2014-10-23 | 2014-10-23 | |
| US62/067,774 | 2014-10-23 | ||
| PCT/US2015/056653 WO2016064999A1 (en) | 2014-10-23 | 2015-10-21 | Novel cho integration sites and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535258A JP2017535258A (ja) | 2017-11-30 |
| JP2017535258A5 true JP2017535258A5 (enExample) | 2018-11-22 |
| JP6668340B2 JP6668340B2 (ja) | 2020-03-18 |
Family
ID=54602002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519646A Active JP6668340B2 (ja) | 2014-10-23 | 2015-10-21 | 新規ｃｈｏ組込み部位およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9816110B2 (enExample) |
| EP (1) | EP3209785B1 (enExample) |
| JP (1) | JP6668340B2 (enExample) |
| KR (1) | KR102243243B1 (enExample) |
| CN (1) | CN107109434A (enExample) |
| AR (1) | AR102420A1 (enExample) |
| AU (1) | AU2015335921B2 (enExample) |
| BR (1) | BR112017008022A2 (enExample) |
| CA (1) | CA2965495C (enExample) |
| EA (1) | EA037255B1 (enExample) |
| IL (1) | IL251674B (enExample) |
| MX (1) | MX2017005306A (enExample) |
| MY (1) | MY184103A (enExample) |
| SG (1) | SG11201703149RA (enExample) |
| TW (2) | TWI780847B (enExample) |
| WO (1) | WO2016064999A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY184103A (en) | 2014-10-23 | 2021-03-18 | Regeneron Pharma | Novel cho integration sites and uses thereof |
| US10329594B1 (en) | 2015-09-03 | 2019-06-25 | CHO Plus, Inc. | Cell lines for high level production of protein-based pharmaceuticals |
| US11649449B2 (en) | 2015-09-03 | 2023-05-16 | CHO Plus, Inc. | Hybrid cell lines for high level production of a target protein |
| WO2017184831A1 (en) | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| KR102906454B1 (ko) * | 2016-04-20 | 2026-01-02 | 리제너론 파마슈티칼스 인코포레이티드 | 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| EP4130280A3 (en) * | 2016-12-20 | 2023-04-19 | Development Center for Biotechnology | Targeted integration sites in chinese hamster ovary cell genome |
| US20210309988A1 (en) * | 2017-02-07 | 2021-10-07 | Sigma-Aldrich Co. Llc | Stable targeted integration |
| KR102719587B1 (ko) * | 2017-02-17 | 2024-10-17 | 론자 리미티드 | 아데노-관련 바이러스 생산을 위한 포유동물 세포 |
| WO2018175153A1 (en) * | 2017-03-19 | 2018-09-27 | Applied Stemcell, Inc. | Novel integration sites and uses thereof |
| AU2018315428B2 (en) * | 2017-08-11 | 2024-11-14 | Boehringer Ingelheim International Gmbh | Integration sites in CHO cells |
| CN107723276B (zh) * | 2017-11-02 | 2021-08-13 | 上海交通大学 | 一种稳定高表达目标产物的细胞株的构建方法和试剂盒 |
| US20200318106A1 (en) * | 2017-12-22 | 2020-10-08 | Bio-Rad Laboratories, Inc. | Controlling phenotype of organisms with crispr/cas gene targeting |
| WO2019126634A2 (en) * | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Targeted integration of nucleic acids |
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| CN109295093B (zh) * | 2018-10-30 | 2021-08-03 | 江南大学 | 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用 |
| CN109207432B (zh) * | 2018-10-30 | 2021-08-03 | 江南大学 | 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用 |
| CN109295092B (zh) * | 2018-10-30 | 2021-06-29 | 江南大学 | 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用 |
| CN109321604B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用 |
| CN109337927B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用 |
| CN109136193B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用 |
| SG11202106523SA (en) * | 2018-12-21 | 2021-07-29 | Genentech Inc | Targeted integration of nucleic acids |
| MX2021011903A (es) | 2019-04-02 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Método para introducir un gen extraño específico del objetivo. |
| CA3141233A1 (en) | 2019-06-26 | 2020-12-30 | Shahram Misaghi | Randomized configuration targeted integration of nucleic acids |
| EP3901266A1 (en) * | 2020-04-22 | 2021-10-27 | LEK Pharmaceuticals d.d. | Super-enhancers for recombinant gene expression in cho cells |
| WO2021247672A1 (en) * | 2020-06-02 | 2021-12-09 | Catalent Pharma Solutions, Llc | Nucleic acid constructs for protein manufacture |
| CN116096907A (zh) * | 2020-06-24 | 2023-05-09 | 基因泰克公司 | 核酸的靶向整合 |
| AR123777A1 (es) | 2020-10-15 | 2023-01-11 | Hoffmann La Roche | Constructos de ácido nucleico para transcripción de arn va |
| CN113755447B (zh) * | 2021-09-23 | 2022-04-29 | 云舟生物科技(广州)股份有限公司 | 一种用于生产腺病毒的293a细胞株及其制备与应用 |
| US12234472B2 (en) | 2021-10-18 | 2025-02-25 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| EP4419691A1 (en) | 2021-10-18 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Controlled transcription of polynucleotides |
| JP2024539076A (ja) | 2021-10-18 | 2024-10-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 安定した組み込み部位を産生するために組み込まれたＣａｓ９遺伝子を含む哺乳動物細胞、並びに安定した組み込み部位及び他の部位を含む哺乳動物細胞 |
| JP2025503925A (ja) * | 2022-01-28 | 2025-02-06 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 異種移植のための遺伝子改変 |
| CN117305334B (zh) * | 2022-06-21 | 2024-11-08 | 深圳太力生物技术有限责任公司 | 靶向整合细胞及其制备方法、生产目标基因表达产物的方法 |
| US20240167984A1 (en) | 2022-11-18 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Methods for detecting and determining protein structures and stability in fluids, including biological fluids |
| CN118726475B (zh) * | 2023-03-28 | 2025-07-08 | 深圳太力生物技术有限责任公司 | 核酸、重组载体、靶向整合细胞、基因表达方法和应用 |
| WO2024211287A1 (en) * | 2023-04-03 | 2024-10-10 | Seagen Inc. | Production cell lines with targeted integration sites |
| WO2025054526A1 (en) | 2023-09-07 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Production and purification of covalently surface modified adeno-associated virus |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| ATE539161T1 (de) | 1998-07-21 | 2012-01-15 | Millipore Corp | Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid |
| US6521419B1 (en) * | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| AU2002254529A1 (en) | 2001-04-04 | 2002-10-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Nucleic acids for transgene expression |
| US20040045043A1 (en) * | 2002-05-20 | 2004-03-04 | Finney Robert E. | Compositions and methods for generating conditional knockouts |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US7771997B2 (en) | 2007-06-04 | 2010-08-10 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| CN102625655B (zh) * | 2008-12-04 | 2016-07-06 | 桑格摩生物科学股份有限公司 | 使用锌指核酸酶在大鼠中进行基因组编辑 |
| SG10201914098YA (en) | 2011-04-05 | 2020-02-27 | Scripps Research Inst | Chromosomal landing pads and related uses |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| EP2714936B1 (en) * | 2011-06-01 | 2018-12-12 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| JP6188703B2 (ja) * | 2011-10-27 | 2017-08-30 | サンガモ セラピューティクス， インコーポレイテッド | Ｈｐｒｔ遺伝子座を修飾するための方法および組成物 |
| JP6559063B2 (ja) | 2012-05-07 | 2019-08-14 | サンガモ セラピューティクス， インコーポレイテッド | 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物 |
| MY184103A (en) | 2014-10-23 | 2021-03-18 | Regeneron Pharma | Novel cho integration sites and uses thereof |
-
2015
- 2015-10-21 MY MYPI2017701254A patent/MY184103A/en unknown
- 2015-10-21 CN CN201580069889.1A patent/CN107109434A/zh active Pending
- 2015-10-21 KR KR1020177012465A patent/KR102243243B1/ko active Active
- 2015-10-21 JP JP2017519646A patent/JP6668340B2/ja active Active
- 2015-10-21 WO PCT/US2015/056653 patent/WO2016064999A1/en not_active Ceased
- 2015-10-21 MX MX2017005306A patent/MX2017005306A/es unknown
- 2015-10-21 AU AU2015335921A patent/AU2015335921B2/en active Active
- 2015-10-21 CA CA2965495A patent/CA2965495C/en active Active
- 2015-10-21 EA EA201790698A patent/EA037255B1/ru unknown
- 2015-10-21 EP EP15797495.7A patent/EP3209785B1/en active Active
- 2015-10-21 BR BR112017008022-2A patent/BR112017008022A2/pt not_active Application Discontinuation
- 2015-10-21 SG SG11201703149RA patent/SG11201703149RA/en unknown
- 2015-10-21 US US14/919,300 patent/US9816110B2/en active Active
- 2015-10-22 TW TW110128495A patent/TWI780847B/zh active
- 2015-10-22 TW TW104134716A patent/TWI747808B/zh active
- 2015-10-23 AR ARP150103445A patent/AR102420A1/es unknown
-
2017
- 2017-04-09 IL IL251674A patent/IL251674B/en active IP Right Grant
- 2017-10-13 US US15/783,525 patent/US20180030480A1/en not_active Abandoned
-
2019
- 2019-09-19 US US16/575,506 patent/US11788102B2/en active Active
-
2021
- 2021-02-12 US US17/175,025 patent/US11268109B2/en active Active
-
2023
- 2023-09-06 US US18/461,798 patent/US20240018553A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535258A5 (enExample) | ||
| AU2016202122B2 (en) | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof | |
| US20230322956A1 (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| Massarwa et al. | WIP/WASp-based actin-polymerization machinery is essential for myoblast fusion in Drosophila | |
| Nozaki et al. | BBS1 is involved in retrograde trafficking of ciliary GPCRs in the context of the BBSome complex | |
| KR101778317B1 (ko) | 사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법 | |
| JP2019514358A5 (enExample) | ||
| CN109195986B (zh) | 基于使用表达增强性基因座来制备抗体的组合物和方法 | |
| TW202028466A (zh) | 編輯RNAs的方法以及組成物 | |
| EP4074833A1 (en) | Restricted immunoglobulin heavy chain mice | |
| JP2017535258A (ja) | 新規ｃｈｏ組込み部位およびその使用 | |
| JP2017514501A5 (enExample) | ||
| KR20010024296A (ko) | 벡터 구조체와 세포 ｄｎａ의 비상동 재조합법에 의한내생 유전자 발현 | |
| JP2018513681A5 (enExample) | ||
| JP2016513669A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| JP2016515508A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| JP2019515666A5 (enExample) | ||
| RU2020114785A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| JP2019505216A5 (enExample) | ||
| CN115427558A (zh) | 用于高效且特异性基因组编辑的位点-特异性重组酶的融合物 | |
| JP6817944B2 (ja) | 最適化治療用分子を製造する方法 | |
| CN112469732A (zh) | 使用胰岛素样生长因子1-加密脱氧核糖核酸构建体及肝细胞生长因子-加密脱氧核糖核酸构建体的神经病变治疗 | |
| Rosenfeld et al. | A primer set for comprehensive amplification of V-genes from rhesus macaque origin based on repertoire sequencing |